Table 1.

Characteristics of eligible studies in this meta-analysis

Author	Year	Country	No. of Patient	Tumor type	Method	Cut-off	Outcome	Analysis	Antibody	NOS
Somasiri	2004	Canada	272	Breast cancer	IHC	IHC ≥ 50%	CSS	K-M Curve	M	7
Hsu	2010	Taiwan	303	Renal cell carcinoma	IHC	IHC score ≥ 1	OS, CSS, MFS	Multivariate	P	8
Larsson	2011	Sweden	626	Colorectal cancer	IHC	IHC score ≥ 3	OS, CSS	Multivariate	P	8
Cipollone	2012	Canada	479	Ovarian cancer	IHC	IHC score ≥ 1	DFS	K-M Curve	M	8
Larsson	2012	Sweden	607	Colorectal cancer	IHC	IHC score ≥ 3	OS, DFS, TTR	Multivariate	P	9
Binder	2013	America	181	Glioblastoma multiforme	IHC	NA	OS	Multivariate	NA	7
Boman	2013	Sweden	100	Urothelial bladder cancer	IHC	IHC score ≥ 3	OS	Multivariate	M/P	7
Boman	2013	Sweden	343	Urothelial bladder cancer	IHC	IHC score ≥ 3	OS, CSS, PFS	Multivariate	M/P	8
Forse	2013	Canada	698	Breast cancer	IHC	IHC score ≥ 3	DFS	Multivariate	P	9
Kaprio	2014	Finland	840	Colorectal cancer	IHC	IHC score ≥ 3	CSS	K-M Curve	M/P	9
Heby	2015	Sweden	175	Pancreatic and periampullary adenocarcinoma	IHC	IHC score ≥ 2	OS, DFS	Multivariate	P	7
Laitinen	2015	Finland	337	Gastric cancer	IHC	IHC score ≥ 1	CSS	Multivariate	M/P	8
Saukkonen	2015	Finland	189	Pancreatic ductal adenocarcinoma	IHC	IHC score ≥ 3	CSS	Multivariate	M/P	7
Borg	2016	Sweden	106	Esophageal cancer	IHC	IHC score ≥ 1	OS, TTR	K-M Curve	P	7
Borg	2016	Sweden	65	Gastric cancer	IHC	IHC score ≥ 1	OS, TTR	K-M Curve	p	7
Chijiiwa	2016	Japan	70	Pancreatic cancer	IHC	IHC score ≥ 4	OS, DFS	K-M Curve	M	7
Taniuchi	2016	Japan	102	Pancreatic cancer	IHC	IHC score ≥ 3	OS	Multivariate	P	7
Kusumoto	2017	Japan	114	Lung adenocarcinoma	IHC	IHC score ≥ 1	OS, DFS, CSS	K-M Curve	NA	8
Yuan	2018	China	87	Colorectal cancer	IHC	IHC score ≥ 3	OS	Multivariate	M	7
Zhang	2018	China	54	Gastric cancer	IHC	IHC score ≥ 1	OS, DFS	Multivariate	NA	7

IHC Immunohistochemistry, NA Not Available, OS Overall Survival, DFS Disease-free Survival, CSS Cancer-specific Survival, NOS Newcastle-Ottawa Scale